Latin America Cancer Immunotherapy Market

Latin American Cancer Immunotherapy Market Size (2023 to 2028)

The Latin America Cancer Immunotherapy Market size is estimated to grow from USD 13.23 Billion in 2023 to USD 23.42 Billion by the end of 2028, growing at a CAGR of 12.10% from 2023 to 2028.

Immunotherapy is a type of treatment option that helps your immune system fight against cancer. According to the World Health Organization report, in 2018, 9.6 million people have cancer. Also, 1 out of 6 deaths is due to cancer globally. Usually, the immune system helps the body fight against infections and other diseases.  Cancer immunotherapy helps prevent the growth of cancer cells, inhibiting the cancer cells from spreading across the body. It helps the immune system to fight better against cancer cells.

The key drivers influencing the growth of the Latin America Cancer immunotherapy market are increasing cancer, changing lifestyle, Smoking and excessive alcohol intake, high efficacy of immunotherapy compared to other treatments, fewer side effects associated with cancer immunotherapy, reduced chance of recurrence of cancer.

Various cancers such as Melanoma show resistance towards chemotherapy and radiation therapies, Cost of cancer therapies, limited information on cancer immunobiology are the significant factors limiting the market's growth.

This research report on the Latin American Cancer Immunotherapy market has been segmented & sub-segmented into the following categories:

By Type of Therapies: 

• Immune System Modulators
• Immune Checkpoint Inhibitors
• Monoclonal Antibodies

By Area of Therapy: 

• Blood Cancer
• Prostate Cancer
• Melanoma
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Other Minor Areas

By Country: 

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America

Geographically, the Brazilian cancer immunotherapy market holds the highest shares of the Latin American market from the past few years and is to continue the same growth rate in the forecast period. Increasing incidences of chronic diseases such as cancer are a significant factor for the market to grow. On-going research and development activities are escalating the demand of the market. Brazil has its healthcare system for cancer treatment in 2017, i.e., Brazil's National health system. They developed cancer Care policies in favor of ordinary people.

Mexican cancer immunotherapy market is positioned second in leading dominant shares of the market. Growing support from government organizations and a rise in the number of people who have cancer are likely to propel the market's demand. 

KEY MARKET PLAYERS:

Notable companies operating in the Latin American cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp and Immunomedics.